[ad_1]
Marinomed Biotech AG, a globally operating biopharmaceutical company, is pleased to announce today that Swansea University Medical School is planning a clinical trial with Iota / kappa-carrageenan nasal spray as a COVID-19 prophylaxis for healthcare professionals (ICE-COVID) .
The investigator-initiated study in Swansea will recruit 480 healthcare professionals who will manage COVID-19 patients during the pandemic. The aim of the study was to evaluate the efficacy of Carragelose nasal and throat spray in reducing the rate, severity and duration of COVID-19 infections. Additional endpoints include infection with other respiratory viruses, usability of the spray for prophylaxis, and effects on quality-adjusted life years (QALYs). The ongoing clinical trial is supported by Marinomed Biotech AG, creator and licensee of Carragelose and Boots UK; the Carragelose nasal spray used in the study is marketed as Boots Dual Defense in the UK.
The double-blind study design has been finalized and is expected to begin shortly. The study population will be equally randomized into a treatment group (0.12 mg / ml iota-carrageenan / 0.4 mg / ml kappa-carrageenan in 0.5% saline) and a placebo group (0 saline , 5%) and will apply this study regimen three times a day, one dose in each nostril and three throat sprays, over the course of eight weeks.
With the world in the devastating grip of this SARS-CoV2 pandemic and nurses and doctors particularly exposed, we look forward to these very important clinical data from the Swansea study. Our pivotal clinical data for Carragelose have demonstrated the attenuation of several coronavirus infections. Marinomed was able to demonstrate neutralizing activity against the novel coronavirus in vitro earlier this year. We have very good reasons to expect and hope that the study will confirm our in vitro results and help validate Carragelose Nasal Spray as a COVID-19 prophylaxis for the vulnerable community of healthcare professionals, protecting them from contracting COVID-19 infections. “
Dr. Eva Prieschl-Grassauer, Scientific Director of Marinomed
“After seeing the effects of this pandemic on colleagues caring for COVID-19 patients, we wanted to find a way for research to help protect frontline NHS personnel,” said Dr Zita Jessop. , principal investigator for clinical trials and clinical scientist at Swansea University. “Previous studies have highlighted the effectiveness of iota-carrageenan nasal sprays against coronaviruses, indicating promise against SARS-CoV-2. If the results of this randomized placebo-controlled clinical trial are as positive as we expect, this has the potential to add an extra prevention strategy in the fight against COVID-19, “he added.
.
[ad_2]
Source link
